A new medicine for pancreatic cancer has shown very good results in a large clinical trial. The medicine, called daraxonrasib, helped patients with advanced cancer live almost twice as long as those who took standard chemotherapy. Patients using daraxonrasib survived a median of 13.2 months, while those with chemotherapy survived 6.7 months.

The medicine works by targeting a genetic mutation found in many pancreatic cancer cases. This mutation makes cancer cells grow too quickly. By changing this process, the medicine stops tumours from growing so fast.

Pancreatic cancer is usually hard to treat and often found late. Researchers say the new results are a major step. They hope the drug will now begin faster reviews by health agencies and help more patients soon.